COMPASS Pathways nag-ulat ng positibong Phase 3 COMP006 data para sa COMP360 sa TRD

COMP006, ang pangalawang pivotal Phase 3 trial, nakamit ang pangunahing endpoint na may lubos na istatistikal na makabuluhang pagpapabuti ng MADRS sa Linggo 6 (P<0.001) at nagpakita ng patuloy na paghihiwalay hanggang 26 linggo. Kasama ang COMP005, ang dalawang trial ay nagbibigay ng pare-pareho at matibay na data ng bisa sa >1,000 TRD na pasyente, na sumusuporta sa patuloy na rolling NDA submission na inaasahang makumpleto sa Q4 2026.

Mahahalagang fact

Na-file: Hul 7, 2026, 10:33 AM
Kaganapan: Topline na resulta
Direksyon: Positibo
Kumpanya: CMPSCompass Pathways
Asset: COMP360
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Tagal ng bisa: 26 linggo
kalahok: higit sa 1,000
Pagsusumite ng NDA: Q4 2026
Mga pagsubok sa Phase 3: COMP005 at COMP006
Pangunahing sukatan ng resulta: Pagbabago sa MADRS sa Linggo 6, P<0.001

Sipi mula sa source

EX-99.1 2 a8-kdated7july2026ex991.htm EX-99.1 a8-kdated7july2026ex991 © Compass Pathways | 1 Compass Pathways Phase 3 COMP006 data review July 7, 2026 © Compass Pathways | 2 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “continue,” “could,” “estimate,” “expect,” “may,” “might,” “plan,” “potential,” “project,” “target,” “will,” “would,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These forward-looking statements includ

SEC 8-K